Clinical Trials Logo

IPF clinical trials

View clinical trials related to IPF.

Filter by:

NCT ID: NCT06310746 Recruiting - IPF Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects

Start date: April 23, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and in vivo experiments. This is a randomized, double-blind, placebo-controlled study with single dose escalation design to assess the safety, PK, and immunogenicity of HLX6018 in healthy subjects. It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg). This is the first-in-human study of the investigational product.

NCT ID: NCT06181370 Recruiting - IPF Clinical Trials

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C). Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.

NCT ID: NCT05895565 Recruiting - IPF Clinical Trials

A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

Start date: May 19, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1b randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study of PMG1015 in idiopathic pulmonary fibrosis (IPF) subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after MAD.

NCT ID: NCT05803850 Completed - IPF Clinical Trials

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Start date: March 28, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of HNC1058 given to healthy subjects, compared to placebo.

NCT ID: NCT05570058 Recruiting - Fibrosis Clinical Trials

Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Start date: September 8, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.

NCT ID: NCT05353556 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Effects of Home-based Inspiratory Muscle Training in Patients With IPF

Start date: February 21, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effects of the home-based inspiratory muscle training program on lung functions, dyspnea, inspiratory muscle strength, functional capacity and quality of life in patients with idiopathic pulmonary fibrosis. Patients are evaluated before the inspiratory muscle training and after 8 weeks of training.

NCT ID: NCT05349760 Withdrawn - IPF Clinical Trials

A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

Start date: March 2023
Phase: Phase 2
Study type: Interventional

AMB-053-01 is a randomized, placebo controlled, multicenter study which will enroll approximately 36 subjects ages 40 and older with IPF for 6 doses over a 24-week dosing period.

NCT ID: NCT05193136 Recruiting - COPD Clinical Trials

Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

Start date: December 10, 2021
Phase:
Study type: Observational

We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.

NCT ID: NCT05190211 Recruiting - IPF Clinical Trials

Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

It is to determine the effectiveness of different telerehabilitation exercise programs received to 2 groups randomly formed in idiopathic pulmonary fibrosis (IPF) patients. The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TGr) and Video Group (VGr).

NCT ID: NCT05147597 Recruiting - IPF Clinical Trials

Turkish Validity and Reliability of SGRQ-I

Start date: January 9, 2022
Phase:
Study type: Observational

The Saint George Respiratory Questionnaire (SGRQ) questionnaire is a frequently used questionnaire in the respiratory patient group, and the Turkish version of this questionnaire, which was created for use in idiopathic pulmonary fibrosis patients, is not available. There is no commonly used quality of life questionnaire in patients with idiopathic pulmonary fibrosis. The aim of the study is to translate and validate the SGRQ idiopathic pulmonary fibrosis version of questionnaire into Turkish.